Understand the genitourinary partnering landscape using intelligence from 319 real-world collaboration and licensing deals.
Genitourinary Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 319 partnering deals involving genitourinary assets, technologies and development programs.
Genitourinary partnering encompasses a diverse range of oncology and non-oncology indications, technologies and stages of development, with transaction structures reflecting different scientific, clinical and commercial strategies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which genitourinary opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in genitourinary partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when considered alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable transactions and prospective partners.
Identify comparable genitourinary transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking genitourinary opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable genitourinary assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building genitourinary portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying genitourinary deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Genitourinary Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 319 partnering deals involving genitourinary assets, technologies and development programs.
Genitourinary partnering encompasses a diverse range of oncology and non-oncology indications, technologies and stages of development, with transaction structures reflecting different scientific, clinical and commercial strategies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which genitourinary opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in genitourinary partnering.
Understand the genitourinary partnering landscape
The report analyzes genitourinary dealmaking from 2016 to 2026, including:
- Trends in genitourinary partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active genitourinary dealmakers
- Leading deals by disclosed value
- How genitourinary partnering activity is evolving
Benchmark genitourinary deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when considered alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading genitourinary dealmakers and prospective partners
The report identifies the most active companies in genitourinary partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking genitourinary opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in specific technologies or approaches
- Competitors pursuing similar external innovation strategies
Compare partnering activity across genitourinary indications and targets
Genitourinary disease encompasses a range of distinct oncology and non-oncology opportunities with differing clinical, competitive and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable transactions and prospective partners.
Understand how genitourinary agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected genitourinary transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive genitourinary deal directory
The report includes a comprehensive directory of 319 genitourinary collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable genitourinary transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking genitourinary opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable genitourinary assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building genitourinary portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide genitourinary intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying genitourinary deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in genitourinary dealmaking
Chapter 3 - Financial deal terms for genitourinary partnering
Chapter 4 - Leading genitourinary deals and dealmakers
Chapter 5 - Genitourinary contract document directory
Chapter 6 - Genitourinary dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 20/20 BioLabs
- Abbott Laboratories
- Abbvie
- Acer Therapeutics
- Acerus
- Acurx Pharmaceuticals
- AdaptivEndo
- Advanz Pharma
- Akcea Therapeutics
- Akebia Therapeutics
- Alberta Health Services
- Albert Einstein College of Medicine
- Alexion Pharmaceuticals
- Algernon Pharmaceuticals
- Alio Medical
- AliveCor
- Alivio Therapeutics
- Allecra Therapeutics
- Allergan
- Alloy Therapeutics
- Alnylam Pharmaceuticals
- Altasciences
- Altavant Sciences
- AM-Pharma
- Ambry Genetics
- American Lung Association
- American Renal Associates
- American Urological Association
- Amerigen Pharmaceuticals
- Amgen
- Amicus Therapeutics
- Ampio Pharmaceuticals
- Amplity Health
- Angion Biomedica
- Antares Pharma
- Anteris Bio
- Anthem
- Apellis Pharmaceuticals
- Aquestive Therapeutics
- Aquinox Pharmaceuticals
- Arch Biopartners
- Ardelyx
- Arena Pharmaceuticals
- Arrevus
- Ascend Clinical
- Asieris Pharmaceuticals
- ASKA Pharmaceuticals
- Aspect Biosystems
- Assistance Publique-Hôpitaux de Paris
- Astek Diagnostics
- Astellas Pharma
- AstraZeneca
- Astute Medical
- Aurinia Pharmaceuticals
- AWAK Technologies
- Ayogo Health
- Aziyo Biologics
- Baxter International
- Bayer
- Baylor Health Care System
- Beacon Discovery
- Beckman Coulter
- Beijing Mabworks Biotech
- BenevolentAI
- Beth Israel Deaconess Medical Center
- Biim Ultrasound
- Bio-Techne
- BIOASTER
- Biocoat
- Biomedical Advanced Research and Development Authority
- bioMerieux
- Bioqube Ventures
- Blacksmith Medicines
- Blue Cross Blue Shield Association
- Blue Water Biotech
- Boehringer Ingelheim
- Bridge Medicines
- Brigham and Women's Hospital
- BrightInsight
- Bristol-Myers Squibb
- Caelum Biosciences
- Caldera Pharmaceuticals
- Calliditas Therapeutics
- CAMP4 Therapeutics
- Cantex Pharmaceuticals
- Cara Therapeutics
- CARB-X
- Cardio Renal Society of America
- CareDx
- CB2 Therapeutics
- CELLINK
- Centogene
- ChemoCentryx
- Chiesi Farmaceutici
- China Medical System
- Chinook Therapeutics
- Cigna Healthcare
- CJ Corp
- Cleveland Clinic
- Climb Bio
- Clinical Consultants International
- Clinical Laserthermia Systems (CLS)
- CloudCath
- Cogentix Medical
- Columbia University
- Cook Biotech
- Corino Therapeutics
- Cornell University
- Creative Medical Technologies
- Cricket Health
- CromSource
- CrossBay Medical
- CSL
- CSPC Pharmaceutical Group
- CytoSorbents
- Dalton Pharma Services
- Danish Innovation Fund
- Datavant
- DaVita
- Debiopharm
- Defense Threat Reduction Agency
- DemeTECH
- Department of Veterans Affairs
- Dialco Medical
- Dicerna Pharmaceuticals
- DILIsym Services
- Dimerix Biosciences
- Diurnal
- Drexel University
- Duchesnay
- Ecole Polytechnique Federale de Lausanne
- eGenesis
- EirGen Pharma
- Eledon Pharmaceuticals
- Elexopharm
- Eliaz Therapeutics
- Eli Lilly
- Enable Injections
- Enteris Biopharma
- Enzyvant Science
- Epigen Biosciences
- Erasmus University Medical Center
- Erlangen University Hospital
- Eton Pharmaceuticals
- Eurofins Scientific
- Everest Medicines
- Eversana
- Evestra
- Evotec
- Exagen Diagnostics
- ExCEEd Orphan
- Ferring Pharmaceuticals
- Fimbrion Therapeutics
- FirstString Research
- Flagship Pioneering
- Forendo Pharma
- Fortress Biotech
- Fosun Pharmaceutical
- Foundation for International Urogynecological Assistance
- Frazier Healthcare Ventures
- Frenova Renal Research
- Fresenius
- Fresenius Kabi Pharmaceuticals
- Fresenius Medical Care
- Fuji Yakuhin
- Fundacion Progreso y Salud
- Gedeon Richter
- Geisinger Medical Center
- Genewiz
- Genexo
- George Clinical
- Gilead Sciences
- Goldfinch Bio
- GSK
- Hangzhou Zhongmei Huadong Pharmaceutical
- Hansa Biopharma
- Harvard Stem Cell Institute
- Harvard University
- Health Logic Interactive
- Helix BioPharma
- HemoCleanse
- Henlius Biotech
- HHS Technology Group
- HIBio
- Horizon Therapeutics
- Humana
- HydroCision
- Hyloris Pharmaceuticals
- Ibidi
- Icahn School of Medicine at Mount Sinai
- Ideal Medical Solutions
- IGAN Biosciences
- Ilias Biologics
- Immedica
- ImmuneID
- ImpediMed
- Innovation Network Corporation
- Innovus Pharmaceuticals
- Insilico Medicine
- IntelGenx
- Intelligent Scopes
- IntrinsiQ
- Inventia Healthcare
- Invitae
- InVivo
- Ion Channel Innovations
- Ionis Pharmaceuticals
- Itochu
- Jana Care
- Janssen Pharmaceuticals
- Janssen Research & Development
- Japan Tobacco
- JCR Pharmaceuticals
- Johns Hopkins University
- Jolt Health
- JSR
- Juventas Therapeutics
- Kahn-Sagol-Maccabi
- Kaken Pharmaceutical
- Karolinska Institute
- KBI BioPharma
- Keryx Biopharmaceuticals
- Key Technologies
- Kezar Life Sciences
- Kumamoto University
- Kyorin Pharmaceutical
- Kyowa Hakko Kirin
- Kyowa Hakko Kogyo
- Laborie Medical Technologies
- Lavasta Pharma
- Leiden University
- Lifeline Vascular Care
- LifeStrands Genomics
- Locus Biosciences
- Lupus Foundation of America (LFA)
- Lupus Research Alliance
- Lupus Therapeutics
- Luqa Pharmaceuticals
- Marathon Medical
- Massachusetts General Hospital
- Mathematica
- Mauna Kea Technologies
- Mayo Clinic
- Maze Therapeutics
- Medeologix
- MediBeacon
- Medical University South Carolina
- Medice Arzneimittel Pütter
- MedImmune
- Medinova
- Medipal Holdings
- Medison Pharma
- Medline
- Melinta Therapeutics
- Memorial Sloan Kettering Cancer Center
- Menarini
- Merck Animal Health
- Merck Sharpe & Dohme
- Merz
- Mesh Bio
- Metabolon
- MetaSight Diagnostics
- Methuselah Foundation
- Metrion Biosciences
- Michigan Medicine
- MicrobeDx
- Mironid
- Mission Therapeutics
- Mitobridge
- Morehouse School of Medicine
- MorphoSys
- Mount Sinai Health System
- MultiOmic Health
- Murdoch Childrens Research Institute
- Myovant Sciences
- Nanostics Precision Health
- NanoVibronix
- Nantes University
- Nashville Biosciences
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- National Institutes of Health Clinical Center
- National Kidney Foundation
- National Research Council Canada
- NCPC GeneTech
- Neokidney
- Nephria Bio
- Neptune Technologies & Bioressources
- Nestle Health Science
- NeuralStem
- Nicoya
- Nkarta Therapeutics
- NMI Natural and Medical Sciences Institute
- Nosopharm
- Novartis
- Novo Integrated Sciences
- Novo Nordisk
- Numares
- Oklahoma Medical Research Foundation
- OmniVision Technologies
- One Biosciences
- Onegevity
- OpGen
- OPKO Health
- Organovo
- OrsoBio
- OSE Immunotherapeutics
- Ospedale San Raffaele
- Otsuka
- Outpost Medicine
- Outset Medical
- Palette Life Sciences
- Palleon Pharmaceuticals
- Panion & BF Biotech
- Par Pharmaceutical
- PatenSee
- Patheon N.V.
- Penn State College of Medicine
- Pharmacological research Institute Mario Negri
- Pherecydes Pharma
- Pierre Fabre
- Pivotal bioVenture Partners
- Poiesis Medical
- Poxel
- PPD
- Precision Image Analysis
- Procept BioRobotics
- Promepla
- Promethera Biosciences
- Prometic Life Sciences
- Proteomics International
- Purdue Pharma
- PureTech Health
- PX Therapeutics
- Pythagoras Medical
- Q32 Bio
- Quebec Urological Association Foundation
- Quimica Europea
- Quotient Therapeutics
- REACH Kidney Care
- Reata Pharmaceuticals
- Rebiotix
- ReCor Medical
- Rectify Pharmaceuticals
- Rediscovery Life Sciences
- Regulus Therapeutics
- Relief Therapeutics
- Renalys Pharma
- RenalytixAI
- Resverlogix
- ReviR Therapeutics
- Roche
- Roche Diagnostics
- Rockwell Medical
- ROi (Resource Optimization & Innovation)
- Roivant Sciences
- ROKIT Healthcare
- Royal Children’s Hospital
- Samsung Bioepis
- SandboxAQ
- Sanguina
- Saniona
- SanReno Therapeutics
- Sarfez Pharmaceuticals
- Satellite Healthcare
- Scanwell Health
- Scohia Pharma
- Scynexis
- Selecta Biosciences
- Selexis
- Sequentify
- SERB Pharmaceuticals
- Shanghai Haini Pharmaceutical
- Siemens Healthineers
- Silence Therapeutics
- Singapore General Hospital
- SinoMab Bioscience
- Sinovant Sciences
- Somatus
- SOM Biotech
- Sonacare Medical
- Specialty Renal Products
- Spectrum Pharmaceuticals
- Spero Therapeutics
- Sphingotec
- Spruce Biosciences
- STADA Arzneimittel
- Stanford University
- Sumitomo Dainippon Pharma
- Sumitomo Pharmaceuticals
- Sumitovant Biopharma
- Sun Pharmaceutical
- Suzhou Sinovent Pharmaceuticals
- Swedish Orphan Biovitrum
- Swixx Biopharma
- SyMap Medical
- Sysmex America
- TaiGen Biotechnology
- Takeda Pharmaceutical
- Teijin
- Telara Pharma
- Telix Pharmaceuticals
- Terumo Blood and Cell Technologies
- Tetra Bio-Pharma
- Teva Pharmaceutical Industries
- The Medicines Company
- The United Laboratories
- Thoeris
- Thorne Research
- TONIX Pharmaceuticals
- toSense
- Travere Therapeutics
- Trestle Biotherapeutics
- Tufts Medical Center
- twoXAR
- TxCell
- Ubiquigent
- UCB
- Unicycive Therapeutics
- Unilife
- University of Arkansas
- University of Bristol
- University of California
- San Diego
- University of California Berkeley
- University of California San Francisco
- University of Cambridge
- University of Glasgow
- University of Houston
- University of Miami
- University of Michigan
- University of Pennsylvania
- University of Sheffield
- University of Texas
- University of Texas at El Paso
- University of Toronto
- University of Utah
- University of Western Ontario
- UpScriptHealth
- Ur24Technology
- UroGen Pharma
- Urotronic
- Urovant Sciences
- US Air Force
- US Army Medical Research Institute of Infectious Diseases
- Vanderbilt University
- Vaneltix Pharma
- Varian Medical Systems
- Variant Bio
- VenatoRx
- Vensica Medical
- Ventus Therapeutics
- Verana Health
- Vertex Pharmaceuticals
- Viatris
- Vifor-Fresenius Medical Care Renal Pharma
- Vifor Pharma
- Vinnova
- VisiQuate
- Vizient
- vTv Therapeutics
- Weill Cornell Medical College
- Winhealth Pharma Group
- Worldwide Clinical Trials
- Wuxi Apptec Laboratory Services
- Xisle Pharma Ventures Trust
- Xortx Therapeutics
- Yeda Research and Development Company
- Yonsei University Severance Hospital
- Zai Lab
- Zhejiang Ausun Pharmaceutical
- Zifo
- Zydus Cadila
- ZyVersa Therapeutics
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
